On Sept. 3, 2020, Humanigen announced the first case-control data of lenzilumab in severe COVID-19 demonstrated an 80% reduction in relative risk of invasive mechanical ventilation and/or death for patients treated with lenzilumab compared to the matched control group.

Lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, is being evaluated in an ongoing Phase III trial and was selected by the National Institutes of Health (NIH) for its COVID-19 Big Effect Trial.

Humanigen said the manuscript of the study titled “GM-CSF neutralization with lenzilumab in severe COVID-19 patients: A case-control study” was published in Mayo Clinic Proceedings, a premier peer-reviewed journal.